ClinicalTrials.gg
Status unknownNCT01554761Updated Mar 15, 2012

Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia

A Phase 4 interventional study of phacoemulsification and Pentacam (Oculus,Germany)examination in Astigmatism and Cataract, sponsored by China Medical University, China. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-03-15.

Sponsored by China Medical University, China · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2012), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study is to evaluate the necessity of considering posterior corneal toricity on refractive outcome of patients with cataracts and corneal astigmatism after implantation of intraocular lenses.

This is determined by comparing total corneal and refractive astigmatism,and by comparing the expected refractive result with actual refractive astigmatism postoperatively,using total corneal and anterior corneal astigmatism to calculate respectively.

02

Conditions studied

  • Astigmatism
  • Cataract

Keywords

  • astigmatism
  • pseudophakia
03

In context

Astigmatism

417 studies on the registry are indexed under Astigmatism; 50 are open to participants now.

This study's planned enrollment of 30 is below the median of 55 across 325 interventional studies indexed under Astigmatism.

Browse Astigmatism studies →

Lead sponsor

China Medical University, China is the lead sponsor of 94 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • cataract candidates
  • preoperative corneal regular astigmatism >0.75D
  • Willing and able to complete all required postoperative visits
  • Able to comprehend and sign a statement of

Exclusion criteria

Exclusion Criteria:

  • significant intraocular lenses tilt or decentration
  • corneal scarring
  • Irregular corneal astigmatism
  • other ocular diseases
  • surgical complication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Interventions

  • Procedurephacoemulsification

    After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).

  • DevicePentacam (Oculus,Germany)examination

    Total corneal astigmatism is obtained by Pentacam at every visit.

06

What researchers measure

Primary outcomes

  1. Pentacam-derived corneal astigmatism

    Time frame: 3month postoperatively

  2. refraction

    Time frame: 3month postoperatively

07

Study locations

1 of 1 sites recruiting
  • Eye hospital of China Medical Univerisity
    Shenyang, Liaoning 110005, China
    Recruiting
    • Jinsong Zhang, MD · Contact+86 13066667486
    • Qi Sun, MD · Sub investigator
    • Cheng Peng, MD · Sub investigator
    • Jiangyue Zhao, MD · Sub investigator
    • Liwei Ma, MD.PhD · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01554761
Lead sponsor
China Medical University, China
Responsible party
Jinsong Zhang (MD,the President of Eye hosptial of China Medical Univerisity,China, China Medical University, China) — Principal investigator
First posted
Mar 15, 2012
Start date
Feb 2012
Primary completion
May 2012 (estimated)
Last update
Mar 15, 2012

Study contacts

Qi Sun, MD
Contact
qisun97@sina.com
+86 15840336028
Jinsong Zhang, MD
principal investigator · Eye Hospital of China Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion